Hemab Therapeutics doses first participant in Phase 1 HMB-003 trial
Hemab Therapeutics said the first participant has been dosed in its Phase 1 clinical trial of HMB-003 for heavy menstrual bleeding management.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.